In the last trading session, 2.1 million 4D Molecular Therapeutics Inc (NASDAQ:FDMT) shares changed hands as the company’s beta touched 2.77. With the company’s per share price at $5.92 changed hands at -$0.01 or -0.17% during last session, the market valuation stood at $273.67M. FDMT’s last price was a discount, traded about -512.33% off its 52-week high of $36.25. The share price had its 52-week low at $4.43, which suggests the last value was 25.17% up since then. When we look at 4D Molecular Therapeutics Inc’s average trading volume, we note the 10-day average is 0.68 million shares, with the 3-month average coming to 887.54K.

Analysts gave the 4D Molecular Therapeutics Inc (FDMT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.82. If we narrow down to specifics, the data shows that 0 out of 4 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended FDMT as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. 4D Molecular Therapeutics Inc’s EPS for the current quarter is expected to be -0.84.

4D Molecular Therapeutics Inc (NASDAQ:FDMT) trade information

Instantly FDMT was in red as seen at the end of in last trading. With action 27.31%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 6.28%, with the 5-day performance at 27.31% in the green. However, in the 30-day time frame, 4D Molecular Therapeutics Inc (NASDAQ:FDMT) is 1.54% up. Looking at the short shares, we see there were 7.67 million shares sold at short interest cover period of 6.9 days.

The consensus price target for the stock as assigned by Wall Street analysts is 37.5, meaning bulls need an upside of 84.21% from its current market value. According to analyst projections, FDMT’s forecast low is 6 with 40 as the target high. To hit the forecast high, the stock’s price needs a -575.68% plunge from its current level, while the stock would need to soar -1.35% for it to hit the projected low.

4D Molecular Therapeutics Inc (FDMT) estimates and forecasts

Data shows that the 4D Molecular Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -63.21% over the past 6 months, a -10.08% in annual growth rate that is considerably lower than the industry average of 17.30%. Year-over-year growth is forecast to reach -93.32% down from the last financial year.

Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 2.28M. 3 analysts are of the opinion that 4D Molecular Therapeutics Inc’s revenue for the current quarter will be 176k. The company’s revenue for the corresponding quarters a year ago was -19k and 28k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 12,121.05%. The estimates for the next quarter sales put growth at 528.57%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -46.35%. The 2025 estimates are for 4D Molecular Therapeutics Inc earnings to decrease by -12.46%, but the outlook for the next 5-year period is at -15.10% per year.

FDMT Dividends

4D Molecular Therapeutics Inc is expected to release its next quarterly earnings report in March.

4D Molecular Therapeutics Inc (NASDAQ:FDMT)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 3.91% of 4D Molecular Therapeutics Inc shares while 113.00% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 117.60%. There are 113.00% institutions holding the 4D Molecular Therapeutics Inc stock share, with RA CAPITAL MANAGEMENT, L.P. the top institutional holder. As of 2024-06-30, the company held 10.3471% of the shares, roughly 5.1 million FDMT shares worth $107.01 million.

BLACKROCK INC. holds the second largest percentage of outstanding shares, with 9.9385% or 4.9 million shares worth $102.79 million as of 2024-06-30.